Pediatr Blood Cancer. 2015 Nov;62(11):2018-20. doi: 10.1002/pbc.25621. Epub 2015 Jun 24.
Author information
- 1
- Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
Abstract
Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
KEYWORDS:
Hodgkin lymphoma; ataxia telangiectasia; brentuximab vedotin
Comment in
- Reply to Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab. [Pediatr Blood Cancer. 2016]
- Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab. [Pediatr Blood Cancer. 2016]
- PMID:
- 26109475
- DOI:
- 10.1002/pbc.25621
- [Indexed for MEDLINE]